Personalis, Inc. hosted "Leveraging comprehensive genomic data for diagnostic capabilities and composite biomarker discovery in immunotherapy," a sponsored symposia during the 2021 SITC Annual Meeting. Available here is the recording from the symposia.Program SummaryTo enable the identification of composite biomarkers that combine tumor- and immune-related information from both DNA and RNA, we have developed the Personalis NeXT platform. By utilizing the expansive feature set, individual analytes can be combined to construct composite biomarker scores that correlate with immunotherapy response. In a cohort of 51 late-stage melanoma patients, the integration of neoantigen burden, HLA LOH, and APM mutational data formed a neoantigen-based composite neoantigen (NEOPS) that more accurately predicted response to checkpoint blockade than other markers such as TMB. The platform has been analytically validated and optimized for use with limited FFPE tissue samples, making it ideal for both research and clinical applications.Sponsored Symposia content and views expressed therein are those of the sponsoring organization and not of SITC.
Personalis, Inc. - Sponsored Symposia00:29:02